Table 4.

Comparison of PBMC HDAC activity among men scheduled for prostate biopsy.

		BSE Mean (SE)			Placebo Mean (SE)		P comparing changes
All	Preintervention (n = 43)	Postintervention (n = 42)	Change (n = 42)	Preintervention (n = 44)	Postintervention (n = 44)	Change (n = 44)
	849.7 (46.7)	1080.0 (45.4)	236.7 (59.0)	937.1 (37.4)	1080.9 (31.4)	143.8 (39.9)	0.14
Cancer	Preintervention (n = 15)	Postintervention (n = 15)	Change (n = 15)	Preintervention (n = 13)	Postintervention (n = 13)	Change (n = 13)
	812.7 (63.5)	1155.1 (61.9)	342.3 (80.6)	1007.3 (51.4)	1053.8 (45.5)	46.6 (65.8)	0.01
NonCancer	Preintervention (n = 28)	Postintervention (n = 27)	Change (n = 27)	Preintervention (n = 31)	Postintervention (n = 31)	Change (n = 31)
	869.5 (63.6)	1038.2 (61.1)	178.0 (78.3)	907.6 (48.0)	1092.2 (40.5)	184.6 (48.2)	0.95

One postintervention sample in sulforaphane group had hemolysis.